1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Hypoxia - Pipeline Review, H2 2014

Hypoxia - Pipeline Review, H2 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 34 pages

Hypoxia - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Hypoxia - Pipeline Review, H2 2014’, provides an overview of the Hypoxia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypoxia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypoxia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypoxia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hypoxia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hypoxia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hypoxia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hypoxia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hypoxia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Hypoxia - Pipeline Review, H2 2014
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Hypoxia Overview 6
Therapeutics Development 7
Pipeline Products for Hypoxia - Overview 7
Pipeline Products for Hypoxia - Comparative Analysis 8
Hypoxia - Therapeutics under Development by Companies 9
Hypoxia - Therapeutics under Investigation by Universities/Institutes 10
Hypoxia - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hypoxia - Products under Development by Companies 13
Hypoxia - Products under Investigation by Universities/Institutes 14
Hypoxia - Companies Involved in Therapeutics Development 15
Baxter International Inc. 15
Hypoxia - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Drug Profiles 24
Aes-103 - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
F-15845 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Recombinant Protein to Activate Protein S100-A8 and S100-A9 for Immunology and Respiratory - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Small Molecule to Antagonize Notch Receptor for Pulmonary Arterial Hypertension and Hypoxia - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Hypoxia - Recent Pipeline Updates 30
Hypoxia - Dormant Projects 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables

Number of Products under Development for Hypoxia, H2 2014 7
Number of Products under Development for Hypoxia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Hypoxia - Pipeline by Baxter International Inc., H2 2014 15
Assessment by Monotherapy Products, H2 2014 16
Number of Products by Stage and Target, H2 2014 18
Number of Products by Stage and Mechanism of Action, H2 2014 20
Number of Products by Stage and Route of Administration, H2 2014 21
Number of Products by Stage and Molecule Type, H2 2014 23
Hypoxia Therapeutics - Recent Pipeline Updates, H2 2014 30
Hypoxia - Dormant Projects, H2 2014 32

List of Figures

Number of Products under Development for Hypoxia, H2 2014 7
Number of Products under Development for Hypoxia - Comparative Analysis, H2 2014 8
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Products, H2 2014 12
Assessment by Monotherapy Products, H2 2014 16
Number of Products by Top 10 Targets, H2 2014 17
Number of Products by Stage and Top 10 Targets, H2 2014 17
Number of Products by Top 10 Mechanism of Actions, H2 2014 19
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 19
Number of Products by Top 10 Molecule Types, H2 2014 22
Number of Products by Stage and Top 10 Molecule Types, H2 2014 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market and Blood Disease Statistics

  • December 2016
    8 pages
  • Therapy  

    Blood Disease  

View report >

Cardiovascular Disease Statistics in the US

  • December 2016
    171 pages
  • Cardiovascular ...  

    Therapy  

  • United States  

View report >

Pathology Statistics in the US and the UK

  • December 2016
    12 pages
  • Pathology  

    Digestive Syste...  

    Cancer  

  • United States  

    United Kingdom  

View report >

Related Market Segments :

Therapy

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.